RCUS - Arcus Biosciences, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

Arcus Biosciences, Inc.

3928 Point Eden Way
Hayward, CA 94545
United States

Full Time Employees108

Key Executives

NameTitlePayExercisedYear Born
Dr. Terry J. Rosen Ph.D.Co-Founder, Chairman & CEO296.65kN/A1960
Dr. Juan Carlos JaenCo-Founder, Pres & Director351.2kN/A1958
Ms. Rekha Hemrajani M.B.A.Chief Operating & Financial OfficerN/AN/A1969
Dr. Stephen Young Ph.D.VP of TechnologyN/AN/A1969
Ms. Katherine BockVP of Investor Relations & Corp. StrategyN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.

Corporate Governance

Arcus Biosciences, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.